CN116096705A - 新型化合物 - Google Patents

新型化合物 Download PDF

Info

Publication number
CN116096705A
CN116096705A CN202180053567.3A CN202180053567A CN116096705A CN 116096705 A CN116096705 A CN 116096705A CN 202180053567 A CN202180053567 A CN 202180053567A CN 116096705 A CN116096705 A CN 116096705A
Authority
CN
China
Prior art keywords
acrylamide
methyl
alkyl
dihydro
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180053567.3A
Other languages
English (en)
Chinese (zh)
Inventor
N·米勒
R·鲁特
J·库拉戈夫斯基
R·莫菲
T·拉杜瓦赫蒂
J·麦克林
M·莫罗格鲁
E·塔尔博特
M·罗利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nrg Treatment Co ltd
Original Assignee
Nrg Treatment Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nrg Treatment Co ltd filed Critical Nrg Treatment Co ltd
Publication of CN116096705A publication Critical patent/CN116096705A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/96—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180053567.3A 2020-09-01 2021-09-01 新型化合物 Pending CN116096705A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2013728.7 2020-09-01
GBGB2013728.7A GB202013728D0 (en) 2020-09-01 2020-09-01 Novel compounds
PCT/GB2021/052261 WO2022049376A1 (en) 2020-09-01 2021-09-01 Novel compounds

Publications (1)

Publication Number Publication Date
CN116096705A true CN116096705A (zh) 2023-05-09

Family

ID=72749708

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180053567.3A Pending CN116096705A (zh) 2020-09-01 2021-09-01 新型化合物

Country Status (12)

Country Link
US (1) US20240067614A1 (https=)
EP (1) EP4208442B1 (https=)
JP (1) JP7784430B2 (https=)
KR (1) KR20230069915A (https=)
CN (1) CN116096705A (https=)
AU (1) AU2021337195A1 (https=)
CA (1) CA3190645A1 (https=)
ES (1) ES3055772T3 (https=)
GB (1) GB202013728D0 (https=)
IL (1) IL300900A (https=)
MX (1) MX2023002525A (https=)
WO (1) WO2022049376A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202013731D0 (en) * 2020-09-01 2020-10-14 Nrg Therapeutics Ltd Novel cmpounds
EP4514780A4 (en) * 2022-04-29 2026-04-29 Dong A St Co Ltd BICYCLIC COMPOUNDS USED AS TEAD INHIBITORS
GB202300833D0 (en) 2023-01-19 2023-03-08 Nrg Therapeutics Ltd Novel compounds
CN119306612B (zh) * 2023-07-14 2026-03-20 中国科学院大连化学物理研究所 一种反式氨基茚满的制备方法
CN121866248A (zh) 2023-09-05 2026-04-14 Nrg治疗有限公司 作为mptp抑制剂起作用的吡啶衍生物
GB202410534D0 (en) 2024-07-18 2024-09-04 Nrg Therapeutics Ltd Novel method and uses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948796A (en) * 1988-03-03 1990-08-14 Toyama Chemical Co., Ltd. Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
WO2004037751A2 (en) * 2002-08-29 2004-05-06 Temple University - Of The Commonwealth System Of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
JP2006160916A (ja) * 2004-12-08 2006-06-22 Fuji Photo Film Co Ltd インクジェット用インク組成物及びインクジェット記録方法
CN102264693A (zh) * 2008-10-27 2011-11-30 康金尼亚有限公司 用作线粒体通透性转变抑制剂的丙烯酰胺衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2669270T3 (en) * 2011-01-28 2018-02-26 Sato Pharma Indole-related compounds such as URAT1 inhibitors
US10155936B2 (en) * 2014-12-05 2018-12-18 An2H Discovery Limited Parkin ligase activation methods and compositions
CA2884607A1 (en) 2015-03-11 2016-09-11 Stealth Peptides International, Inc. Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions
GB202013731D0 (en) * 2020-09-01 2020-10-14 Nrg Therapeutics Ltd Novel cmpounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948796A (en) * 1988-03-03 1990-08-14 Toyama Chemical Co., Ltd. Piperazine derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient
WO2004037751A2 (en) * 2002-08-29 2004-05-06 Temple University - Of The Commonwealth System Of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
US20060167317A1 (en) * 2002-08-29 2006-07-27 Temple University- Of The Commonwealth System Of Higher Education Aryl and heteroaryl propene amides, derivatives thereof and therapeutic uses thereof
JP2006160916A (ja) * 2004-12-08 2006-06-22 Fuji Photo Film Co Ltd インクジェット用インク組成物及びインクジェット記録方法
CN102264693A (zh) * 2008-10-27 2011-11-30 康金尼亚有限公司 用作线粒体通透性转变抑制剂的丙烯酰胺衍生物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DANIELE FANCELLI等: "Cinnamic Anilides as New Mitochondrial Permeability Transition Pore Inhibitors Endowed with Ischemia-Reperfusion Injury Protective Effect in Vivo", 《JOURNAL OF MEDICINAL CHEMISTRY》, vol. 57, 11 June 2014 (2014-06-11), pages 5333, XP055464404, DOI: 10.1021/jm500547c *
MAO XIANG CHEN等: "Probing Mitochondrial Permeability Transition Pore Activity in Nucleated Cells and Platelets by High-Throughput Screening Assays Suggests Involvement of Protein Phosphatase 2B in Mitochondrial Dynamics", 《ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES》, vol. 16, no. 8, 1 December 2018 (2018-12-01), pages 3, XP055848095, DOI: 10.1089/adt.2018.872 *
STN，REGISRY: "CAS RN：1268319-90-9", 《STN，REGISRY》, 13 March 2011 (2011-03-13) *
STN，REGISRY: "CAS RN：2362016-29-1", 《STN，REGISRY》, 30 July 2019 (2019-07-30) *
STN，REGISRY: "CAS RN：76381-40-3、76381-39-0、76381-38-9", 《STN，REGISRY》, 13 March 2011 (2011-03-13) *

Also Published As

Publication number Publication date
MX2023002525A (es) 2023-05-17
WO2022049376A1 (en) 2022-03-10
EP4208442A1 (en) 2023-07-12
GB202013728D0 (en) 2020-10-14
JP7784430B2 (ja) 2025-12-11
EP4208442C0 (en) 2025-10-22
US20240067614A1 (en) 2024-02-29
IL300900A (en) 2023-04-01
EP4208442B1 (en) 2025-10-22
AU2021337195A1 (en) 2023-03-02
JP2023539694A (ja) 2023-09-15
KR20230069915A (ko) 2023-05-19
CA3190645A1 (en) 2022-03-10
ES3055772T3 (en) 2026-02-16

Similar Documents

Publication Publication Date Title
CN116096705A (zh) 新型化合物
CN116096712B (zh) 新型化合物
EP2997023B9 (en) Bipyrazole derivatives as jak inhibitors
CN118804911A (zh) 丙烯酰胺化合物
TW202136275A (zh) 嗒𠯤基─噻唑甲醯胺化合物
CN113613649A (zh) 用于治疗囊肿状纤维化的化合物及其治疗方法
CN120641407A (zh) Mptp抑制剂
TWI570127B (zh) 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
US20240247029A1 (en) Interleukin-1 receptor modulators and uses thereof
HK40012259A (en) Bipyrazole derivatives as jak inhibitors
HK40012259B (en) Bipyrazole derivatives as jak inhibitors
HK1221466B (en) Bipyrazole derivatives as jak inhibitors
NZ753637B2 (en) Bipyrazole derivatives as jak inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination